BNP/CALL/ASTRAZENECA/14000/0.1/20.12.24 Stock

BNP/CALL/ASTRAZENECA/14000/0.1/20.12.24 Share Price

DE000PC836G4

Market Closed - Boerse Frankfurt Warrants 08:50:59 07/06/2024 pm IST
0.55 ^EUR	0.00%

Current month	+30.95%
1 month	+25.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart BNP/CALL/ASTRAZENECA/14000/0.1/20.12.24

Latest news about ASTRAZENECA PLC

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer	07/06	AQ
ASTRAZENECA : JP Morgan reiterates its Buy rating	07/06	ZD
Pharma Company Astrazeneca Withdrawing Covid Vaccine Because It's Outdated - Not 'After Admitting to Dangerous Side Effect'	06/06	AQ
Astrazeneca completes £1.5bn Fusion Pharmaceuticals deal	06/06	AQ

More news

Quotes 5-day view

Date	Price	Change
07/24/07	0.55	0.00%
06/24/06	0.55	0.00%
05/24/05	0.55	+12.24%
04/24/04	0.49	+4.26%
03/24/03	0.47	+11.90%

Real-time Boerse Frankfurt Warrants

Last update June 07, 2024 at 08:50 pm IST

More quotes

Static data

Product type	Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	BNP Paribas
WKN	PC836G
ISIN	DE000PC836G4
Date issued	30/04/2024
Strike	14,000 p
Maturity	20/12/2024 (195 Days)
Parity	10 : 1
Emission price	0.31 €
Emission volume	N/A
Settlement	règlement en espèces
Currency	EUR

Technical Indicators

Highest since issue	0.56 €
Lowest since issue	0.34 €
Delta	0.35x
Omega	9.368
Premium	15.25x
Gearing	26.64x
Moneyness	0.8969
Difference Strike	1,444 p
Difference Strike %	+10.31%
Spread	0.01 €
Spread %	1.79%
Theoretical value	0.5550
Implied Volatility	23.70 %
Total Loss Probability	71.04 %
Intrinsic value	0.000000
Present value	0.5550
Break even	14,471.42 €
Theta	-0.02x
Vega	0.04x
Rho	0.02x

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company